Head and neck cancer (HNC) presents challenges due to its heterogeneity, high recurrence rate, and hypoxic microenvironments. Current treatments fall short, leading to high morbidity and mortality. Photodynamic therapy (PDT) offers spatiotemporal tumor control but relies on oxygenation, posing limitations in hypoxic tumors. Combining hypoxia-activated prodrugs with PDT can selectively kill hypoxic tumor cells and reduce the tumor burden. This study proposes using evofosfamide, a hypoxia-activated prodrug, in combination with benzoporphyrin derivative (BPD)-PDT in a 3D spheroids model of HNC. The growth profile, BPD uptake profile, and hypoxia development were investigated. Combination therapy enhanced PDT efficacy in hypoxic HNC spheroids.
|